
AstraZeneca’s cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer
pharmafile | March 13, 2020 | News story | Medical Communications, Research and Development | AstraZeneca, cediranib, lynparza, pharma, trial failure
Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined with Lynparza (olaparib), failed to meet its main goal in clinical trials.
In the US National Cancer Institute-sponsored study, the combo failed to meet its primary endpoint of statistically significant improvement in progression-free survival (PFS) in the intent-to-treat population compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer.
Despite this, the combo’s safety profile was found to be in line with previous data.
“Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer,” said José Baselga, Executive Vice President, Oncology R&D. “We will work closely with NRG Oncology and the NCI to review the full results to inform our ongoing research.”
Ovarian cancer is the eighth most deadly cancer in the world for women. Cediranib fights the disease by inhibiting the expansion of tumours through blocking the growth of the blood vessels that sustain them.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …






